ANI Pharmaceuticals | ANIP - Sales Revenues


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

ANI Pharmaceuticals

ANI Pharmaceuticals reported $106.79M in Sales Revenues for its fiscal quarter ending in March of 2023.


Sales Change
AbbVie ABBV:US USD 12.23B 2.9B
ANI Pharmaceuticals ANIP:US USD 106.79M 12.55M
Depomed DEPO:US USD 42.47M 7.88M
Eli Lilly LLY:US USD 6.96B 341.8M
Emergent BioSolutions EBS:US USD 180.3M 150.4M
Endo International ENDP:US USD 515.27M 40.54M
Heron Therapeutics HRTX:US USD 29.62M 413K
Hikma Pharmaceutical HIK:LN USD 1.3B 91M
Knight Therapeutics Inc GUD:CN CAD 82.6M 942K
Nektar Therapeutics NKTR:US USD 21.59M 429K
Novartis NVS:US USD 13.21B 207M
Perrigo PRGO:US USD 1.18B 26.4M
Sun Pharmaceuticals SUNP:IN INR 109.31B 3.1B
Teva Pharmaceutical Industries Ltd TEVA:IT USD 3.66B 223M